Skip to the content
Please enable JavaScript in your browser to complete this form.
Lemborexant Insomnia Psychiatry Expert Forum
Dear Doctor, thank you for your contributions to the upcoming Eisai Hong Kong Lemborexant Psychiatry Expert Forum. In preparation for the meeting, we would be very grateful if you could spend a moment answering the following short survey.
Q1. Are you currently based in…
*
[Please select]
Public practice
Private practice
Q2. What proportion of the patients you initiate on lemborexant are treatment-naïve?
*
[Please select]
<25%
25–50%
51–75%
>75%
Q3. Please select the 3 most common patient populations in which you have initiated lemborexant.
*
Primary insomnia
Patients with anxiety
Patients with depression
Patients with circadian rhythm disorders
Shift workers
Patients at risk of falls
Patients at risk of adverse consequence from daytime sedation
Stress/anxiety-related arousal
Other
Patients with circadian rhythm disorders_please specify
*
Other_please specify
*
Q4. If prescribing lemborexant as a monotherapy, would you prescribe it…
*
[Please select]
as a 1st line treatment
as 2nd line treatment
as 3rd line treatment
as 4th line treatment or beyond
Q4_please specify
*
Q5. Would you prescribe lemborexant in combination with Z-drugs/ benzodiazepines/ concomitant psychiatric medication?
*
[Please select]
Yes
No
Q6. Approximately what percentage of your patients reported that lemborexant:
a) reduced sleep onset
*
[Please select]
<25%
25–75%
51-75%
>75%
b) reduced wake after sleep onset (WASO)
*
[Please select]
<25%
25–75%
51-75%
>75%
c) increased total sleep time
*
[Please select]
<25%
25–75%
51-75%
>75%
Q7. Have any of your patients on lemborexant experienced adverse events (AE)?
*
[Please select]
Yes
No
Q7_please specify
*
Q8. If a patient reports an AE that does not require cessation of treatment due to safety, what is your preferred approach for management?
*
[Please select]
Stop treatment and do not re-start
Stop treatment and restart once symptoms resolve
Adjust dose (reduce dose of lemborexant and/or concomitant drugs)
Maintain dose and monitor closely
Depends on type or severity of the event
Q8_please specify
*
Q9. Are there any conditions where you would NOT consider initating lemborexant?
*
[Please select]
Yes
No
Q9_please specify
*
Submit